🦊/Investors

Gilde Healthcare

Venture capital

Utrecht · Seed–Late Stage · 24 people tracked

Also known as GILDE HEALTHCARE PARTNERS B.V.

Find your way into Gilde Healthcare

3,020 people in our graph share verified history with the Gilde Healthcare team — schools, employers, funds. One of them is your warm intro.

Chris Bischoffunlockedknows Jasper van Gorp · together at INSEAD (overlapped)
×2knows the team · via Brown University
×4knows the team · via University of Cambridge
×2knows the team · via McKinsey & Company
knows the team · via Arthur D. Little
×2knows the team · via Vlerick Business School
Fox Verdict
Sign up to see your fit

Investment thesis

Gilde Healthcare invests in impactful companies addressing healthcare and climate challenges through three strategies. Its Healthcare Private Equity fund backs profitable businesses that support the healthcare sector, including providers, medical product suppliers, and service companies. The Healthcare Venture & Growth fund targets disruptive companies in medtech, digital health, medical instruments, and therapeutics. The Climate Solutions fund invests in profitable companies focused on energy transition, biodiversity, and waste & pollution. The firm combines operating and financial expertise across a transatlantic team and integrates ESG and measurable impact into its investment approach.

Source: firm website, verified Sep 15, 2026.

Stage
Seed–Late Stage
Check
$1.1M – $55M
HQ
Utrecht, NL
Leads rounds
Follows
Instruments
Equity
Founded
1999
Last 12 months
3 investments
AUM
$2.8B
VC funds
3
Tracked investments
30
Acquisitions
1

Team · 24 people

from the firm's website & public directories
Rafael Natanek· General Partner Private Equity
Edward Hanlon· Investment Director Venture&Growth
Besmire Ahmati· Senior Associate Investor Relations & Fundraising

Senior Associate focused on investor relations and fundraising, based in the support office.

Christiaan Sap· Operational Partner
Giel Modderman· Associate, Private Equityin
Karthik Bolisetty· Investment Manager Healthtech Venture&Growthin

Investment Manager within the Healthtech Venture&Growth team.

Lara Hilgert· Senior Associate, Private Equityin
Rene Bernards· Operational Partner

Professor Dr. Rene Bernards is an Operational Partner in Gilde Healthcare's Venture&Growth team.

Tristan Maguet· Senior Associate Therapeutics Venture&Growthin
Wessel van 't Klooster· Analyst, Private Equity

Wessel van 't Klooster joined Gilde Healthcare's Private Equity team in 2026 as an analyst.

What they invest in

from 28 of 30 portfolio companies

Healthtech ×22Medical Devices ×18Biotech ×13Hardware ×7Digital Health ×5AI & Machine Learning ×3Deep Tech ×3Data & Infrastructure ×1

HQs:United States×15Netherlands×3United Kingdom×2Denmark×1Ireland×1

Investments · 31 tracked

founders shown can be your intro path

By year:2026 · 22025 · 42024 · 62023 · 12022 · 12021 · 12020 · 32019 · 220 dated

Draupnirdraupnir.bioinJul 2024✓ verified

Draupnir Bio develops targeted protein degradation therapies using sortilin-based lysosome targeting chimeras to clear extracellular and membrane-bound protein aggregates in proteinopathies.

BiotechDeep TechMedical DevicesCopenhagen, DK

Simon Glerup(Professor)inCamilla Gustafsen(Professor)inPeder Søndergaard Madsen(Professor)Peter Seeberger(Professor)

Co-investorsInkefMC Healthcare VenturesNovo Holdings

Purespringpurespringtx.comin𝕏Oct 2024✓ verified

Purespring develops genetic therapies targeting podocytes to treat renal diseases through its proprietary GlomThera platform.

BiotechDigital HealthHealthtechMedical Devices

Moin Saleem(Co-founder & Chief Scientific Advisor)in

Co-investorsSofinnova PartnersForbionAdvent Life SciencesBritish Patient Capital

Vesper Medicalvespermedical.comin𝕏May 2019✓ verified

Vesper Medical develops a modular venous stent portfolio designed to address the anatomical challenges of the iliac and femoral veins for treating deep venous disease.

HealthtechMedical DevicesWayne, US

Bruce J. Shook(President and CEO)Monica Klos(Executive Officer)inNeil Hattangadi(Director)inPeter Schneider(Director)Mark Garcia(Director)Dennis W. Wahr(Director)

Co-investorsNew Enterprise Associates (NEA)Lightstone VenturesVensana Capital415 Capital

visit www.levicept.comlevicept.com✓ verified

Levicept is a company in the life sciences sector with backing from prominent healthcare and pharmaceutical investors including Medicxi, Pfizer Ventures, Gilde Healthcare, and Advent Life Sciences.

BiotechHealthtechMedical Devices

Simon Westbrook(Founder and CSO)

Co-investorsAdvent Life SciencesIndex VenturesMedicxiPfizer VenturesPfizer Venture Investments

Vs3vs3medical.comin✓ verified

VS3 Medical is a medical device company developing the VS3 Medical Stent System, an investigational neurovascular implant designed to treat symptomatic venous sinus stenosis within the dural venous sinus anatomy.

HardwareHealthtechMedical Devices

Co-investorsAPERTURE Venture PartnersUS Venture Partners

.406 Ventures406ventures.comFeb 2026 · $23.7M

.406 Ventures is an early-stage venture capital firm that partners with founders in healthcare, data and AI, and cybersecurity to help grow their companies.

Maria Cirino(Founder)in

Co-investorsGrandBanks CapitalAlleyCorpCVS Health VenturesSandbox Clinical Ventures

Ablative Solutionsablativesolutions.com

HealthtechWakefield, US

Tim A. Fischell(Executive Officer, Director)inKate Rumrill(Executive Officer, Director)Lisa Mastromattei(Executive Officer)Ronald D Bache(Executive Officer, Director)Vartan E. Ghazarossian(Executive Officer, Director)David R. Fischell(Director)

Co-investorsMichigan Capital NetworkBioStar VenturesMAF

Acacia Pharmaeagleus.cominAug 2020

Eagle Pharmaceuticals develops and commercializes specialty pharmaceutical products for acute care and oncology, including injectable medications for procedural sedation, chemotherapy, lymphomas, and malignant hyperthermia management.

BiotechHealthtechMedical DevicesIndianapolis, US

Co-investorsF-Prime Capital

Agendiaagendia.comin𝕏

Agendia develops genomic technology and diagnostic tests for breast cancer patients.

AI & Machine LearningBiotechDigital HealthMedical DevicesIrvine, US

Laura van 't Veer(Co-founder)inRené Bernards(Co-founder)inProf. Laura van 't Veer, PhD(Chief Research Officer, Co-founder)Prof. Dr. René Bernards, PhD(Co-Founder and Scientific Advisor)Mark R. Straley(CEO)in

Co-investorsKorys

Alleviant Medical Incalleviantmedical.comin𝕏Feb 2025

Alleviant Medical develops an investigational minimally invasive medical device using interatrial shunt therapy to treat heart failure patients, currently in FDA-approved clinical trials (ALLAY-HF and ALLAY-HFrEF).

BiotechHealthtechMedical DevicesAustin, US

Adam Berman(Executive Officer, Director)inJacob Kriegel(Executive Officer, Director)Avni Patel(Executive Officer, Director)Christopher Alex Arevalos(Executive Officer, Director)Albertien Greijdanus(Executive Officer, Director)

BoardGeoff Pardo(Director)in

Co-investorsBroadview VenturesRiverVest Venture PartnersTMC Venture FundCadence Healthcare VenturesGilmartin Capital LLCS3 Ventures+1 more

Amphistaamphista.comin𝕏

Amphista Therapeutics develops next-generation targeted protein degradation (TPD) medicines using its proprietary Targeted Glue technology, which is engineered to selectively trigger the destruction of disease-causing proteins.

BiotechCambridge, GB

Louise Modis(Chief Executive Officer)inMartin Pass(Chief Development Officer)inGiles Brown(Executive VP Drug Discovery)in

Co-investorsAdvent Life SciencesNovartis Venture FundSV Health InvestorsDementia Discovery FundEuropean Investment FundForbion+2 more

Argá Medtechargamedtech.comFeb 2024

Argá Medtech is developing a non-thermal cardiac ablation system based on a proprietary Pulsed Field Ablation (PFA) technology using sine wave energy and a proprietary catheter to treat atrial fibrillation and other heart arrhythmias.

HardwareHealthtechMedical Devices

Co-investorsAdvent Life SciencesEarlybird Venture Capital

Axonicsaxonicsmodulation.cominNov 2019 · $110M

Axonics Modulation, now part of Boston Scientific, develops medical devices in the field of neuromodulation therapies for patients.

HealthtechMedical Devices

Raymond Cohenin

Co-investorsAPERTURE Venture Partners

Big Healthbighealth.com𝕏Jan 2022 · $75M

Big Health develops digital treatments and care programs for mental health conditions, including cognitive behavioral therapy-based solutions for insomnia and other mental health issues.

Digital HealthHealthtechMental Health

Peter Hames(Co-founder)inColin Espie(Co-founder)

Co-investors.406 VenturesAlleyCorpBlue Venture FundsIndex VenturesInnovation Global CapitalKaiser Permanente Ventures+8 more

DaylightRxdaylightrx.comOct 2024

Elmsford, US

Jonathan Taqqu(Executive Officer, Director)

BoardJohn Lee(Director)

Co-investorsHealthy Ventures.406 VenturesAlleyCorpCVS Health VenturesSandbox Clinical Ventures

FIRE1fire1foundry.comin𝕏Jan 2025 · $120M

FIRE1 develops NORM, an implantable sensor placed in the inferior vena cava to directly measure fluid volume in heart failure patients, paired with a self-management platform to help patients engage with their own care.

Digital HealthHardwareMedical DevicesDublin, IE

Co-investorsAndera PartnersLightstone VenturesLongitude CapitalNew Enterprise Associates (NEA)GimvIreland Strategic Investment Fund+5 more

Inari Medicalinarimedical.comin

Inari Medical develops mechanical thrombectomy devices for treating venous thromboembolism conditions, including pulmonary embolism, deep vein thrombosis, in-stent thrombosis, and arteriovenous fistula thrombosis.

HardwareHealthtechMedical DevicesIrvine, US

William H. Hoffman(Executive Officer, Director)inRobert Rosenbluth(Executive Officer, Director)

BoardDonald Milder(Director)Kirk Nielsen(Director)inJonathan Root(Director)inBrian Cox(Director)

Co-investorsUS Venture PartnersVensana CapitalVersant Ventures

Inova Labsinovalabs.comacquired by ResMed

Developed lightweight portable oxygen concentrators; acquired by ResMed.

HealthtechAustin, US

John B. Rush(Executive Officer, Director)Daniel Jensen(Executive Officer)

BoardGeoff Pardo(Director)inStephen M. Salmon(Director)Richard Lin(Director)Roderick A. Young(Director)

Co-investorsLatterell Venture Partners

LAVA Therapeuticslavatherapeutics.comin𝕏Sep 2020

LAVA develops the Gammabody platform, which generates bispecific antibodies that activate gamma-delta T cells to treat cancer by directing immune cells to tumors and triggering anti-cancer immune responses.

AI & Machine LearningBiotechHealthtechMedical Devices

Ton AdanginHans van der Vliet(Head of Innovation)inSteve Hurly(Chief Executive Officer)Oxana Polyakova(Chief Scientific Officer)in

Co-investorsMRL Ventures FundSanofi VenturesYsios CapitalREDMILE

LUMICKSlumicks.comin𝕏Apr 2021 · $93M

LUMICKS develops life science research tools that measure and apply forces around biological interactions to link structural and 'omics analysis to functional outcomes at the molecular and cellular level.

BiotechDeep TechHardwareMedical Devices

Andrea(Co-founder & Chief Scientific Officer)Gerrit(Co-founder & Director of Product Management and Marketing)Hugo(CEO)Edmee(Chief Financial Officer)Hannah(HR Director)

Co-investorsLauxera Capital PartnersSoftBank Vision FundEuropean Investment BankIrving InvestorsPura Vida InvestmentsT. Rowe Price

Mainstayadmithub.comin𝕏Feb 2024

AdmitHub provides AI-powered success coaching and conversation tools for higher education institutions to improve student engagement, retention, and outcomes.

AI & Machine LearningEdTechHR TechArlington, US

Andrew Magliozzi(Founder)in

Co-investorsFundersClubMichelson 20MM FoundationNXT VenturesTechstarsAlly Bridge GroupFountain Healthcare Partners+3 more

Mainstay Medicalmainstay-medical.cominFeb 2024

HealthtechPlymouth, US

Dan Sachs(Director)Peter Crosby(Executive Officer, Director)inJason Hannonin

BoardManus Rogan(Director)inAntoine Papiernik(Director)in

Co-investorsFountain Healthcare PartnersSofinnova PartnersAlly Bridge GroupViking Global Investors

Moximedmoximed.com

HealthtechFremont, US

Anton Clifford(Executive Officer)inJames Leech(Executive Officer)inChristopher Gleason(Executive Officer)inKevin K. Sidow(Executive Officer, Director)

BoardJoshua Makower(Director)Shahzad Malik(Director)in

Co-investorsLightstone VenturesNew Enterprise Associates (NEA)Runway Growth CapitalAdvent Life SciencesGBS Venture Partners Ltd.Vertex Ventures HC

Noema Pharmanoemapharma.cominNov 2025

Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs.

BiotechHealthtechMedical Devices

Ilise Lombardo(Chief Executive Officer)inVolker Knappertz(Executive Vice President of Research & Development)inMichael Samar(Chief Financial Officer)inRob Lasser(Chief Medical Officer)in

Co-investorsBioMedPartnersJeito CapitalRoche Venture FundSofinnova PartnersEQTEQT Life Sciences+2 more

Okami Medicalokamimedical.comin𝕏

Okami Medical develops the LOBO vascular occlusion system, an occluder built on high-density, small-pore HDBRAID technology for fast arterial occlusion in the peripheral vasculature, along with SENDERO microcatheters and delivery catheters.

BiotechHardwareHealthtechMedical DevicesAliso Viejo, US

Brian J. Cox(Manager)inRhonda Robb(Executive Officer, Director)inRobert Rosenbluth(Director)

BoardDonald Milder(Director)Jonathan Root(Director)inPaul Lubock(Director)

Co-investorsUS Venture PartnersVensana Capital

Performationperformation.comin

Performation provides business intelligence, data analytics, and monitoring software and consulting for the healthcare sector, covering areas such as care registration, capacity planning, and real-world monitoring.

Data & InfrastructureDigital HealthHealthtechSaaS

Symeressymeres.comin

Symeres provides pharmaceutical quality management systems, drug discovery and development services, and contract manufacturing support for biotech and pharma companies.

BiotechDeep TechEnterprise SoftwareHealthtechNetherlands, NL

Henning Steinhagen(Chief Executive Officer (CEO))inJurgen Berendsen(Chief Financial Officer (CFO))in

Co-investorsKeensight Capital

Tagworks Pharmaceuticalstagworkspharma.comin𝕏Jun 2023

Tagworks Pharmaceuticals develops cancer therapies using its Click-to-Release platform, a chemical reaction that activates antibody-drug conjugates (ADCs), masked immunomodulators, and other prodrugs on-target while deactivating radioimmunotherapies off-target.

BiotechHealthtechMedical DevicesNijmegen, NL

Co-investorsBifLightstone VenturesNew Enterprise Associates (NEA)Novartis Venture FundYsios CapitalClarus Ventures+1 more

Urotronicurotronic.comin𝕏Aug 2025 · $80M

Urotronic develops drug-coated balloons for interventional urology, including the Optilume products for treating benign prostatic hyperplasia (BPH) and urethral strictures.

HealthtechMedical DevicesPlymouth, US

Junfeng Wang(Director)David Perry(Executive Officer, Director)Tan Ching(Director)Hui Hu(Director, Promoter)Lixiao Wang(Director, Promoter)Doug Kohrs(Director)

Co-investorsHM Venture PartnersEnterprise IrelandIreland Strategic Investment FundLegend CapitalLightstone VenturesMVM Life Science Partners+1 more

Vapothermvapotherm.comin𝕏May 2020 · $87M

Vapotherm manufactures high-velocity therapy devices for respiratory distress treatment across patient populations.

HardwareHealthtechMedical DevicesExeter, US

JOSEPH ARMY(Executive Officer, Director)JOHN LANDRY(Executive Officer)in

BoardANTHONY ARNERICH(Director)JASON LETTMAN(Director)GEOFF PARDO(Director)inSAMUEL BRASCH(Director)

Co-investorsCross Creek AdvisorsKaiser Permanente VenturesQuestMark Partners3x5 PartnersMorgenthaler

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

GT Medical Technologies

Exits · 1

1 acquisitions

Inova Labsacq. by ResMed

Portfolio news

latest coverage across their companies

Frequently asked questions

How many investments has Gilde Healthcare made?
Gilde Healthcare has 30 tracked investments, 1 of which have exited, including 8 dated in the last 24 months.
What stage does Gilde Healthcare invest at?
Gilde Healthcare invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What is Gilde Healthcare's typical check size?
Gilde Healthcare typically writes checks of $1.1M – $55M.
What sectors does Gilde Healthcare focus on?
Gilde Healthcare focuses on Biotech, Climate Tech, Digital Health, Energy, Healthtech, Impact & Social Good, Medical Devices.
Where is Gilde Healthcare located?
Gilde Healthcare is headquartered in Utrecht, NL.
Does Gilde Healthcare lead rounds?
Gilde Healthcare typically participates in rounds rather than leading them.

Media · Podcasts & interviews

featuring the team

Janke Dittmer, Gilde Healthcare Partners

Invest Europe · Janke Dittmer

Investment Strategy in Health Tech Industry - Janke Dittmer, Gilde Healthcare Partners

Tech Tour · Janke Dittmer

Images

Gilde Healthcare photoGilde Healthcare photoGilde Healthcare photoGilde Healthcare photoGilde Healthcare photoGilde Healthcare photo

Similar investors

Featured in lists